Eisai与渤健公司宣布Leqembi® Iqlik™皮下注射维持剂量在美国上市,用于治疗早期阿尔茨海默病

美股速递
Oct 07

Eisai与渤健公司联合宣布,用于治疗早期阿尔茨海默病的Leqembi® Iqlik™(Lecanemab-Irmb)皮下注射维持剂量已在美国正式上市。

这一治疗方案为早期阿尔茨海默病患者提供了新的治疗选择,通过皮下注射的方式进行维持治疗,有望为患者带来更便利的用药体验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10